Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS


Phase Early 1 Results N/A

Eligibility Criteria

Inclusion Criteria

- Any patient with suspected brain tumor diagnosed by MRI
- Patients undergoing neuro-imaging evaluation by the neurosurgical service for other indications (e.g. vascular malformations, traumatic brain injury, ischemic and hemorrhagic stroke, CNS infections, and neuro-degenerative diseases)

Exclusion Criteria

- Informed consent cannot be obtained either from the patient or legal representative
- Severe coexisting or terminal systemic disease that limits life expectancy or that may interfere with the conduct of the study
- Contraindication to MRI (metal implants)
- Hemosiderosis/hemochromatosis
- Need for sedation or anesthesia (claustrophobia) that will not otherwise be undertaken as part of routine clinical care (e.g. routine MRI under sedation already planned)
- Known hypersensitivity to Feraheme (ferumoxytol) or any of its components
- Iron overload from any cause (not just hemosiderosis or hemochromatosis), even if secondary to frequent blood transfusions, severe chronic hemolysis, excess dietary or parenteral iron, or any other etiology